for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Nuvectra Corp

NVTR.OQ

Latest Trade

1.53USD

Change

0.09(+6.25%)

Volume

49,306

Today's Range

1.39

 - 

1.53

52 Week Range

1.30

 - 

25.17

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.44
Open
1.46
Volume
49,306
3M AVG Volume
13.45
Today's High
1.53
Today's Low
1.39
52 Week High
25.17
52 Week Low
1.30
Shares Out (MIL)
17.89
Market Cap (MIL)
25.75
Forward P/E
-0.63
Dividend (Yield %)
--

Next Event

Nuvectra Corp Annual Shareholders Meeting

Latest Developments

More

Nuvectra Corp Says Implementing Reduction In Force Plan That Is Expected To Result In Termination Of About 20% To 25% Of Employees During Q3 2019

Nuvectra Is Currently Evaluating All Options, Including A Sale Or Merger Of Company, To Finance Expected Growth Of Nuvectra Business

Nuvectra Reports Q2 Loss Per Share Of $0.62

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Nuvectra Corp

Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company's Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company's commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company's neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).

Industry

Medical Equipment & Supplies

Contact Info

5830 Granite Pkwy Ste 1100

+1.972.6684107

http://www.qiggroup.com/

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.1K
EPS (USD)

2016

-3.740

2017

-4.220

2018

-3.250

2019(E)

-2.393
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.53
Price To Book (MRQ)
0.37
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
64.23
LT Debt To Equity (MRQ)
57.76
Return on Investment (TTM)
-35.41
Return on Equity (TTM)
-30.42

Latest News

BRIEF-Nuvectra Q4 Loss Per Share $0.80

* NUVECTRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Nuvectra Secures $45 Million Second Amendment To Existing Loan And Security Agreement

* NUVECTRA SECURES $45 MILLION SECOND AMENDMENT TO EXISTING LOAN AND SECURITY AGREEMENT

BRIEF-Nuvectra Says Public Offering Of 2.83 Mln Shares Priced At $8 Per Share

* SAYS PUBLIC OFFERING OF 2.83 MILLION COMMON SHARES PRICED AT $8.00PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Nuvectra Sees Q4 Revenue $11.5 Mln To $12 Mln

* NUVECTRA ANNOUNCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2017 REVENUE

BRIEF-Nuvectra reports Q3 loss per share $1.09

* Q3 revenue rose 102 percent to $7.6 million Source text for Eikon: Further company coverage:

BRIEF-Nuvectra corp files for mixed shelf of upto $100 mln

* Nuvectra Corp files for mixed shelf of upto $100 million - sec filing Source text : http://bit.ly/2hQeDbP Further company coverage:

BRIEF-Nuvectra corp says effective Aug. 31, co entered into amended and restated development agreement with Aleva Neurotherapeutics - SEC filing

* Nuvectra Corp - effective august 31, co entered into amended and restated development agreement with Aleva Neurotherapeutics, S.A - SEC filing

BRIEF-Nuvectra Q2 loss per share $1.07

* Q2 revenue rose 183 percent to $7.2 million Source text for Eikon: Further company coverage:

BRIEF-Nuvectra unit enters into business property lease agreement

* Nuvectra Corp - effective July 1, 2017, unit entered into a business property lease agreement with BMT Ann Arbor, Llc Source text: (http://bit.ly/2u7IQEO) Further company coverage:

BRIEF-Nuvectra enters second amendment to development agreement with Aleva Neurotherapeutics

* Nuvectra- effective june 19, co entered second amendment to development agreement with aleva neurotherapeutics, s.a to amend agreement dated jan 29, 2016

BRIEF-Nuvectra files regulatory submission with FDA for Algovita MRI-conditional approval

* Nuvectra files regulatory submission with fda for Algovita MRI-conditional approval

BRIEF-Nuvectra reports Q1 loss per share $1.27

* Q1 revenue rose 144.4 percent to $5.0 million Source text for Eikon: Further company coverage:

BRIEF-Nuvectra amends deal with Aleva to modify payment schedule

* Nuvectra - effective March 30, co entered into amendment to development agreement with Aleva Neurotherapeutics, S.A to amend development agreement between Aleva and co

BRIEF-Nuvectra Q4 loss per share $1.27

* nuvectra™ reports fourth quarter and full year 2016 financial results

BRIEF-Nuvectra extends timeline of existing credit facility

* Reached agreement with lenders of $45 million credit facility to extend availability of final two tranches of facility Source text for Eikon: Further company coverage:

BRIEF-Nuvectra Q3 revenue rose 196.3 pct to $3.8 mln

* Q3 revenue rose 196.3 percent to $3.8 million Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up